Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have demonstrated that pirfenidone reduces lung function decline, decreases mortality and improves progression-free survival....

Descripción completa

Detalles Bibliográficos
Autores principales: Lancaster, Lisa H., de Andrade, Joao A., Zibrak, Joseph D., Padilla, Maria L., Albera, Carlo, Nathan, Steven D., Wijsenbeek, Marlies S., Stauffer, John L., Kirchgaessler, Klaus-Uwe, Costabel, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488585/
https://www.ncbi.nlm.nih.gov/pubmed/29212837
http://dx.doi.org/10.1183/16000617.0057-2017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488585/
https://www.ncbi.nlm.nih.gov/pubmed/29212837
http://dx.doi.org/10.1183/16000617.0057-2017

Ejemplares similares